Generics - Mylan Laboratories, Pharmaceutical

Filter

Popular Filters

US Appeals Court overturns Copaxone patent decision

28-07-2013

Israel-based generics giant Teva Pharmaceutical Industries ((NYSE: TEVA) said on Friday (July 26) that…

CopaxoneGenericsLegalMomenta PharmaceuticalsMylan LaboratoriesNatco PharmaNeurologicalNorth AmericaNovartisPatentsPharmaceuticalSandozTeva Pharmaceutical Industries

Mylan strikes deal for Parkinson's disease drug Stalevo

26-07-2013

US generics firm Mylan (Nasdaq: MYL) and Finland-based drugmaker Orion Corp (Nasdaq OMX Helsinki: ORNAV)…

GenericsLicensingMylan LaboratoriesNeurologicalNorth AmericaOrion CorpPharmaceuticalStalevo

Mylan victorious in patent dispute with Teva

18-07-2013

US generic drugmaker Mylan (Nasdaq: MYL) says that Israel-based Teva Pharmaceuticals Industries (NYSE:…

GenericsMylan LaboratoriesNorth AmericaPatentsPerforomistPharmaceuticalTeva Pharmaceutical Industries

US District Court issues final judgment in favor of Mylan in Brovana patent dispute

09-07-2013

US generics and specialty drugmaker Mylan (Nasdaq: MYL) revealed yesterday (July 8) that the US District…

BrovanaDainippon Sumitomo PharmaGenericsLegalMylan LaboratoriesNorth AmericaPatentsPerforomistPharmaceuticalRespiratory and PulmonarySunovion

EU Commission fines Lundbeck and other Pharmas over "pay-for-delay" deals

19-06-2013

In a much awaited decision following its investigations of patent settlements (or pay-for-delay deals)…

ActaviscitalopramEuropeFinancialGenericsLegalLundbeckMerck KGaAMylan LaboratoriesNeurologicalPatentsPharmaceuticalRanbaxy Laboratories

InSite Vision joins Merck & Co and Pfizer in patent infringement law suit against

17-06-2013

InSite Vision (OTC BB: INSV) that it will US pharma giants join Merck & CO (NYSE: MRK) and Pfizer (NYSE:…

AzaSiteGenericsInSite VisionLegalMerck & CoMylan LaboratoriesNorth AmericaOphthalmicsPatentsPfizerPharmaceutical

Mylan settles with Shionogi and Andrx over Fortamet; Merck & Co diagnostics deal with Luminex

14-03-2013

US generic drugmaker Mylan (Nasdaq: MYL) has entered into a settlement agreement with Japan's Shionogi…

AndrxDiabetesFortametGenericsLuminexMerck & CoMylan LaboratoriesNeurologicalNorth AmericaPatentsPharmaceuticalShionogi

USPTO grants Pfizer reissue patent for Celebrex, extending term to Dec 2015

06-03-2013

Global pharma behemoth Pfizer (NYSE: PFE) said yesterday that the US Patent & Trademark Office has granted…

Anti-Arthritics/RheumaticsApotexCelebrexGenericsLupinMylan LaboratoriesNorth AmericaPatentsPfizerPharmaceuticalTeva Pharmaceutical IndustriesWatson Pharmaceuticals

Patent cliff: one drugmaker's sorrow is another one's joy

20-01-2013

The patent cliff has seen many drug majors lose their exclusivity on blockbuster drugs to generic makers…

DilantinGenericsLystedaMarkets & MarketingMylan LaboratoriesNorth AmericaPatentsPharmaceuticalWatson Pharmaceuticals

Endo fails in FDA law suit to stop generic Opana ER in USA; Mylan settles with Orion

21-12-2012

The US District Judge Reggie Walton, of the District Court for the District of Columbia, has dismissed…

ActavisComtanEndo PharmaceuticalsGenericsImpax LaboratoriesLegalMylan LaboratoriesNeurologicalNorth AmericaOpana ERPharmaceutical

Regulatory briefs from GSK/Theravance, Allergan and Mylan

19-12-2012

UK pharma giant GlaxoSmithKline (LSE: GSK) and US partner Theravance (Nasdaq: THRX0 have submitted a…

AllerganAnoro ElliptaBotoxEuropeGenericsGenito-urinaryGlaxoSmithKlineMylan LaboratoriesNorth AmericaPharmaceuticalQualaquinRegulationRelvarRespiratory and PulmonaryTheravanceTropical diseases

Pfizer links with SFJ Pharma for dacomitinib trial; settles with Mylan

10-09-2012

SFJ Pharmaceuticals Group, a global drug development group of companies which provides a unique co-development…

dacomitinibDetrol LAGastro-intestinalsGenericsLegalMylan LaboratoriesNorth AmericaOncologyPatentsPfizerPharmaceuticalResearchSFJ Pharmaceuticals

EU Commission focus now on Servier and others re-perindopril antitrust issues

31-07-2012

The European Commission has informed French independent pharmaceutical company Servier and several of…

Cardio-vascularEuropeGenericsLegalMarkets & MarketingMylan LaboratoriesPatentsperindoprilPharmaceuticalServierTeva Pharmaceutical Industries

Teva gets favorable UK Copaxone patent ruling

12-07-2012

Israel-based Teva Pharmaceutical Industries (Nasdaq: TEVA) says that the UK High Court of Justice issued…

CopaxoneEuropeGenericsLegalMylan LaboratoriesNeurologicalPatentsPharmaceuticalTeva Pharmaceutical Industries

US Court upholds AstraZeneca Seroquel XR patent

30-03-2012

In some good news for the company, Anglo-Swedish drug major AstraZeneca (LSE: AZN) announced last night…

Anchen PharmaceuticalsAstraZenecaGenericsMylan LaboratoriesNeurologicalNorth AmericaPatentsPharmaceuticalSeroquel XRTorrent Pharmaceuticals

Roche ups bid for Illumina; M&A speculation on Amylin, Actavis

29-03-2012

There was a plethora of merger and acquisition news coming out yesterday and this morning, first of which…

ActavisAmylinBiotechnologyBristol-Myers SquibbGenericsIlluminaMergers & AcquisitionsMylan LaboratoriesPharmaceuticalRocheWatson Pharmaceuticals

Mylan gets OK for generic Crestor in Canada; Rottapharm deal looks dead

18-03-2012

The Canadian subsidiary of US generic drugmaker Mylan (Nasdaq: MYL) has received approval from Health…

AstraZenecaCardio-vascularCrestorEuropeGenericsMergers & AcquisitionsMylan LaboratoriesNorth AmericaPharmaceuticalRegulationRottapharm

Management changes at Mylan, Transition Thera, Pfizer and ShangPharma

12-12-2011

US generic drug major Mylan (Nasdaq: MYL) has announced the appointment of John Thievon as president…

GenericsManagementMylan LaboratoriesPharmaceuticalShangPharmaTransition Therapeutics

Mylan to acquire Pfizer generic respiratory delivery platform; challenge to GSK

10-11-2011

US generic drug major Mylan (Nasdaq: MYL) has entered into an agreement with global pharma behemoth Pfizer…

Advair DiskusGenericsGlaxoSmithKlineLicensingMylan LaboratoriesPfizerPharmaceuticalRespiratory and PulmonarySeretide

Parexel

Parexel

Back to top